Atogepant Superior for Efficacy, Functional Measures in Migraine
By Elana Gotkine HealthDay Reporter
THURSDAY, Dec. 26, 2024 -- For adults with migraine, atogepant 60 mg once daily was superior to placebo for efficacy and functional measures of treatment across three trials, according to research published online Dec. 23 in Neurology.
Richard B. Lipton, M.D., from the Albert Einstein College of Medicine in Bronx, New York, and colleagues examined improvements in efficacy and functional outcomes in the first four weeks of treatment with atogepant 60 mg once daily for the preventive treatment of migraine. The atogepant and placebo treatment arms from three phase 3, multicenter, randomized trials were included (ADVANCE [222 participants with episodic migraine receiving atogepant and 214 receiving placebo]; ELEVATE [151 participants with episodic migraine receiving atogepant and 154 receiving placebo]; and PROGRESS [256 participants with chronic migraine receiving atogepant and 246 receiving placebo]).
The researchers observed greater reductions in the proportion of atogepant-treated participants with a migraine day on day 1. Compared with placebo, the odds ratios were 0.39, 0.53, and 0.63 in ADVANCE, ELEVATE, and PROGRESS, respectively. Reductions in weekly migraine days at weeks 1 to 4 and in monthly migraine days in the first four weeks were seen with atogepant treatment; in addition, at all assessed time points for weeks 1 to 4, Activity Impairment in Migraine-Diary and European Quality-of-Life 5-Dimension 5-Level scores improved compared with placebo.
"The analyses reported here demonstrate the early efficacy and functional improvements of atogepant and address a key unmet need of providing preventive treatment options with early benefits across the spectrum of migraine disease state severity," the authors write.
Several authors disclosed ties to pharmaceutical companies, including AbbVie, which manufactures atogepant and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Liraglutide May Reduce Migraine Burden in Adults With Obesity, Migraine
MONDAY, June 30, 2025 -- For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and Migraine Disability...
Hydrops MRI Accurately Differentiates Meniere Disease, Vestibular Migraine
MONDAY, June 23, 2025 -- The combination of cochlear endolymphatic hydrops (CEH) and vestibular endolymphatic hydrops (VEH) on magnetic resonance imaging (MRI) accurately...
Endolymphatic Sac Decompression Effective for Vertigo, Migraine
WEDNESDAY, May 28, 2025 -- For Meniere disease (MD) patients with migraine, endolymphatic sac decompression (ELSD) is effective, providing postoperative relief of vertigo and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.